SCHEMBL20086572

SCHEMBL20086572

CCOc1nc2n(c1C(C)C)CCCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
GAA P10253 1/20 0.41
LMNA P02545 5/20 0.41
THRB P10828 2/20 0.41
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TP53 P04637 5/20 0.38
SHMT2 P34897 1/20 0.38
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PI4KA P42356 1/20 0.36
PI4K2B Q8TCG2 1/20 0.36
PI4K2A Q9BTU6 1/20 0.36
PI4KB Q9UBF8 1/20 0.36
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
RAB9A P51151 1/20 0.34
HCRTR1 O43613 1/20 0.34
ELANE P08246 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13360504 0.75 POLB (0.44) LMNATHRBMEN1KMT2ATP53
SCHEMBL13328166 0.74 TP53 (0.39) GAALMNATHRBMEN1KMT2A
SCHEMBL20086568 0.72 KDM4E (0.46) MAPTLMNATHRBMEN1KMT2A
SCHEMBL22330447 0.69 MEN1 (0.41) LMNATHRBMEN1KMT2ATP53
SCHEMBL22166764 0.68 KDM4E (0.41) GAALMNAMEN1KMT2ATP53
SCHEMBL19040334 0.67 KDM4E (0.51) MAPTGAALMNATHRBTP53
SCHEMBL22166766 0.66 POLB (0.39) LMNAMEN1KMT2ATP53TSHR
SCHEMBL23546705 0.65 KDM4E (0.38) LMNATP53PI4KAPI4K2BPI4K2A
SCHEMBL23890951 0.64 POLB (0.43) GAALMNATHRBMEN1KMT2A
SCHEMBL20993377 0.64 PDE5A (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10421751-B2 Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-09-24 US disclosed
US-20180111922-A1 DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE LYCERA CORPORATION 2018-04-26 US disclosed
US-20180111922-A1 DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE LYCERA CORPORATION 2018-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180111922-A1 DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE RORB, RORA, RORC MAPT 2750/4885GAA 1589/4885LMNA 4469/4885
US-10421751-B2 Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease RORB, RORA, RORC MAPT 3063/4885GAA 1602/4885LMNA 4310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.